BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 33662837)

  • 1. COVID-19 vaccination in patients with diabetes mellitus: Current concepts, uncertainties and challenges.
    Pal R; Bhadada SK; Misra A
    Diabetes Metab Syndr; 2021; 15(2):505-508. PubMed ID: 33662837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of COVID-19 vaccines in patients with diabetes mellitus: A systematic review.
    Boroumand AB; Forouhi M; Karimi F; Moghadam AS; Naeini LG; Kokabian P; Naderi D
    Front Immunol; 2022; 13():940357. PubMed ID: 36105809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 vaccination during pregnancy: coverage and safety.
    Blakeway H; Prasad S; Kalafat E; Heath PT; Ladhani SN; Le Doare K; Magee LA; O'Brien P; Rezvani A; von Dadelszen P; Khalil A
    Am J Obstet Gynecol; 2022 Feb; 226(2):236.e1-236.e14. PubMed ID: 34389291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 vaccines for cancer patients: a call to action.
    Corti C; Crimini E; Tarantino P; Pravettoni G; Eggermont AMM; Delaloge S; Curigliano G
    Eur J Cancer; 2021 May; 148():316-327. PubMed ID: 33770576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody response following SARS-CoV-2 vaccination among patients with type 2 diabetes mellitus: A systematic review.
    Soetedjo NNM; Iryaningrum MR; Lawrensia S; Permana H
    Diabetes Metab Syndr; 2022 Feb; 16(2):102406. PubMed ID: 35104750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination.
    Ali H; Alterki A; Sindhu S; Alahmad B; Hammad M; Al-Sabah S; Alghounaim M; Jamal MH; Aldei A; Mairza MJ; Husain M; Deverajan S; Ahmad R; Cherian P; Alkhairi I; Alkandari A; Abubaker J; Abu-Farha M; Al-Mulla F
    Front Immunol; 2021; 12():752233. PubMed ID: 34899701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 vaccines: modes of immune activation and future challenges.
    Teijaro JR; Farber DL
    Nat Rev Immunol; 2021 Apr; 21(4):195-197. PubMed ID: 33674759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humoral Immune Response Diversity to Different COVID-19 Vaccines: Implications for the "Green Pass" Policy.
    Polvere I; Parrella A; Zerillo L; Voccola S; Cardinale G; D'Andrea S; Madera JR; Stilo R; Vito P; Zotti T
    Front Immunol; 2022; 13():833085. PubMed ID: 35634315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines.
    Jamshidi E; Asgary A; Shafiekhani P; Khajeamiri Y; Mohamed K; Esmaily H; Jamal Rahi S; Mansouri N
    Hum Vaccin Immunother; 2022 Nov; 18(5):2037384. PubMed ID: 35417285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2.
    Markewitz R; Juhl D; Pauli D; Görg S; Junker R; Rupp J; Engel S; Steinhagen K; Herbst V; Zapf D; Krüger C; Brockmann C; Leypoldt F; Dargvainiene J; Schomburg B; Sharifzadeh S; Nejad LS; Wandinger KP; Ziemann M
    Front Immunol; 2022; 13():811020. PubMed ID: 35126395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?
    Terpos E; Trougakos IP; Karalis V; Ntanasis-Stathopoulos I; Sklirou AD; Bagratuni T; Papanagnou ED; Patseas D; Gumeni S; Malandrakis P; Korompoki E; Dimopoulos MA
    Am J Hematol; 2021 Sep; 96(9):E321-E324. PubMed ID: 34028867
    [No Abstract]   [Full Text] [Related]  

  • 12. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
    Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
    EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 in South Korea: Proper Timing for Easing Mask Mandates After COVID-19 Vaccination.
    Kang YJ
    Disaster Med Public Health Prep; 2022 Oct; 16(5):1832-1834. PubMed ID: 34346306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-SARS-CoV-2 IgA and IgG in human milk after vaccination is dependent on vaccine type and previous SARS-CoV-2 exposure: a longitudinal study.
    Selma-Royo M; Bäuerl C; Mena-Tudela D; Aguilar-Camprubí L; Pérez-Cano FJ; Parra-Llorca A; Lerin C; Martínez-Costa C; Collado MC
    Genome Med; 2022 Apr; 14(1):42. PubMed ID: 35449030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capillary leak syndrome following COVID-19 vaccination: Data from the European pharmacovigilance database Eudravigilance.
    Ruggiero R; Balzano N; Di Napoli R; Mascolo A; Berrino PM; Rafaniello C; Sportiello L; Rossi F; Capuano A
    Front Immunol; 2022; 13():956825. PubMed ID: 36177033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of immune activation of the COVID vaccines: ChAdOx1, BNT162b2, mRNA-1273, BBIBP-CorV, and Gam-COVID-Vac from serological human samples in Hungary showed higher protection after mRNA-based immunization.
    Fodor E; Olmos Calvo I; Kuten-Pella O; Hamar E; Bukva M; Madár Á; Hornyák I; Hinsenkamp A; Hetényi R; Földes F; Brigitta Z; Jakab F; Kemenesi G; Lacza Z
    Eur Rev Med Pharmacol Sci; 2022 Jul; 26(14):5297-5306. PubMed ID: 35916830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination.
    Sheng WH; Chang SY; Lin PH; Hsieh MJ; Chang HH; Cheng CY; Yang HC; Pan CF; Ieong SM; Chao TL; Chen JP; Cheng SH; Chang SC
    J Formos Med Assoc; 2022 Apr; 121(4):766-777. PubMed ID: 35305895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction and exacerbation of subacute cutaneous lupus erythematosus following mRNA-based or adenoviral vector-based SARS-CoV-2 vaccination.
    Kreuter A; Licciardi-Fernandez MJ; Burmann SN; Burkert B; Oellig F; Michalowitz AL
    Clin Exp Dermatol; 2022 Jan; 47(1):161-163. PubMed ID: 34291477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What gastroenterologists should know about SARS-CoV 2 vaccine: World Endoscopy Organization perspective.
    Spadaccini M; Canziani L; Aghemo A; Lleo A; Maselli R; Anderloni A; Carrara S; Fugazza A; Pellegatta G; Galtieri PA; Hassan C; Greenwald D; Pochapin M; Wallace M; Sharma P; Roesch T; Bhandari P; Emura F; Raju GS; Repici A
    United European Gastroenterol J; 2021 Sep; 9(7):787-796. PubMed ID: 34102015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral and Cellular Immune Response After a 3-Dose Heterologous SARS-CoV-2 Vaccination Using the mRNA-BNT162b2 and Viral Vector Ad26COVS1 Vaccine in Hemodialysis Patients.
    Davidovic T; Schimpf J; Abbassi-Nik A; Stockinger R; Sprenger-Mähr H; Lhotta K; Zitt E
    Front Immunol; 2022; 13():907615. PubMed ID: 35812459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.